Copeptin (ct-proavp): a promising marker for evaluation of exact time of onset of diabetes insipidus

Copeptin (CT-proAVP), a stable surrogate of vasopressin precursor acts as a promising marker for evaluation of exact time of onset of diabetes insipidus associated with the surgery of craniopharyngioma, rathke’s cleft cyst and suprasellar pituitary adenoma, and same time indirectly measures and predicts the severity of hypothalamic-pituitary neuronal system damage. Copeptin can prevent the significant clinical consequences resulting from misdiagnosis of serum sodium imbalances and fluid status in the subsequent post-operative period. Overall, copeptin helps in appropriate prescription for vasopressin analogue (e.g. desmopressin) in the post-operative period.